Cancer Statistics, 2006

SEER Cancer Statistics Review, 1975-2003

2006 • 11,387 citations

Cancer Disparities by Race/Ethnicity and Socioeconomic Status

2004 • 1,728 citations

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

2004 • 1,329 citations

Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival

2004 • 1,155 citations

Arming antibodies: prospects and challenges for immunoconjugates

2005 • 1,029 citations

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

2001 • 821 citations

Cancer Statistics for African Americans

2002 • 551 citations

Survival of Blacks and Whites After a Cancer Diagnosis

2002 • 504 citations

Trends in Breast Cancer by Race and Ethnicity

2003 • 459 citations

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

2005 • 446 citations

Efficient Cancer Therapy with a Nanobody-Based Conjugate

2004 • 363 citations

Redesigning Nature's Poisons to Create Anti-Tumor Reagents

1987 • 329 citations

Impact of Reporting Delay and Reporting Error on Cancer Incidence Rates and Trends

2002 • 270 citations

Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies

2005 • 263 citations

Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens.

1990 • 235 citations

An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker

2001 • 223 citations

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

1993 • 221 citations

Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

2005 • 193 citations

Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer

2005 • 186 citations

Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results

2004 • 178 citations

Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys

2005 • 166 citations

Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study

1995 • 165 citations

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

2002 • 158 citations

CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy

2004 • 158 citations

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia

2005 • 153 citations

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines

2000 • 148 citations

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma

1996 • 140 citations

Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice

2003 • 134 citations

Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With ¹³¹I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results

2005 • 132 citations

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

2003 • 132 citations

Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates

2004 • 113 citations

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts

1997 • 112 citations

Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab

2005 • 112 citations

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

2002 • 108 citations

Pivotal Study of Iodine-131–Labeled Chimeric Tumor Necrosis Treatment Radioimmunotherapy in Patients With Advanced Lung Cancer

2005 • 104 citations

Potent and specific antitumor effects of an anti-CD22–targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma

2001 • 104 citations

A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.

2002 • 103 citations

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

2003 • 93 citations

Immunotoxins containing Pseudomonas exotoxin A: a short history

2003 • 92 citations

Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups

2005 • 90 citations

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

2004 • 80 citations

Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.

2003 • 79 citations

Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.

1992 • 75 citations

An Anti-MUC1 Antibody−Calicheamicin Conjugate for Treatment of Solid Tumors. Choice of Linker and Overcoming Drug Resistance

2005 • 73 citations

A New Method of Predicting US and State-Level Cancer Mortality Counts for the Current Calendar Year

2004 • 67 citations

Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.

1987 • 67 citations

Denileukin diftitox: a concise clinical review

2005 • 59 citations

A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.

1999 • 58 citations

Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.

2000 • 57 citations

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin

2005 • 54 citations

A Calicheamicin Conjugate with a Fully Humanized Anti-MUC1 Antibody Shows Potent Antitumor Effects in Breast and Ovarian Tumor Xenografts

2005 • 54 citations

Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.

2003 • 53 citations

Combined ⁹⁰Yttrium‐DOTA‐labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft

2004 • 51 citations

Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.

2003 • 46 citations

Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).

1997 • 46 citations

Antibody–cytotoxic agent conjugates for cancer therapy

2005 • 40 citations

Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.

2002 • 40 citations

Combined modality radioimmunotherapy

2002 • 40 citations

Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies

2005 • 39 citations

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

2005 • 38 citations

Advances in antibody-directed enzyme prodrug therapy.

2005 • 31 citations

Technology evaluation: cantuzumab mertansine, ImmunoGen.

2004 • 18 citations

Generation of an Intensely Potent Anthracycline by a Monoclonal Antibody−β-Galactosidase Conjugate

2005 • 10 citations

Deleted Work

1955 • 0 citations